Ajanta Pharma Limited (AJANTPHARM) - Net Assets
Based on the latest financial reports, Ajanta Pharma Limited (AJANTPHARM) has net assets worth Rs43.15 Billion INR (≈ $466.65 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs56.72 Billion ≈ $613.45 Million USD) and total liabilities (Rs13.57 Billion ≈ $146.80 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Ajanta Pharma Limited's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs43.15 Billion |
| % of Total Assets | 76.07% |
| Annual Growth Rate | 20.06% |
| 5-Year Change | 26.53% |
| 10-Year Change | 223.39% |
| Growth Volatility | 13.36 |
Ajanta Pharma Limited - Net Assets Trend (2005–2025)
This chart illustrates how Ajanta Pharma Limited's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Ajanta Pharma Limited for the complete picture of this company's asset base.
Annual Net Assets for Ajanta Pharma Limited (2005–2025)
The table below shows the annual net assets of Ajanta Pharma Limited from 2005 to 2025. For live valuation and market cap data, see AJANTPHARM company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs37.90 Billion ≈ $409.91 Million |
+6.25% |
| 2024-03-31 | Rs35.67 Billion ≈ $385.80 Million |
+5.29% |
| 2023-03-31 | Rs33.88 Billion ≈ $366.40 Million |
+3.79% |
| 2022-03-31 | Rs32.64 Billion ≈ $353.03 Million |
+8.97% |
| 2021-03-31 | Rs29.96 Billion ≈ $323.97 Million |
+15.27% |
| 2020-03-31 | Rs25.99 Billion ≈ $281.06 Million |
+15.75% |
| 2019-03-31 | Rs22.45 Billion ≈ $242.81 Million |
+9.99% |
| 2018-03-31 | Rs20.41 Billion ≈ $220.77 Million |
+30.22% |
| 2017-03-31 | Rs15.68 Billion ≈ $169.54 Million |
+33.76% |
| 2016-03-31 | Rs11.72 Billion ≈ $126.75 Million |
+39.35% |
| 2015-03-31 | Rs8.41 Billion ≈ $90.96 Million |
+41.76% |
| 2014-03-31 | Rs5.93 Billion ≈ $64.16 Million |
+50.93% |
| 2013-03-31 | Rs3.93 Billion ≈ $42.51 Million |
+31.90% |
| 2012-03-31 | Rs2.98 Billion ≈ $32.23 Million |
+30.24% |
| 2011-03-31 | Rs2.29 Billion ≈ $24.75 Million |
+23.74% |
| 2010-03-31 | Rs1.85 Billion ≈ $20.00 Million |
+17.71% |
| 2009-03-31 | Rs1.57 Billion ≈ $16.99 Million |
+16.24% |
| 2008-03-31 | Rs1.35 Billion ≈ $14.62 Million |
+16.98% |
| 2007-03-31 | Rs1.16 Billion ≈ $12.50 Million |
+6.44% |
| 2006-03-31 | Rs1.09 Billion ≈ $11.74 Million |
+10.97% |
| 2005-03-31 | Rs978.24 Million ≈ $10.58 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ajanta Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3671880000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs36.72 Billion | 96.88% |
| Common Stock | Rs250.70 Million | 0.66% |
| Other Comprehensive Income | Rs896.80 Million | 2.37% |
| Other Components | Rs36.60 Million | 0.10% |
| Total Equity | Rs37.90 Billion | 100.00% |
Ajanta Pharma Limited Competitors by Market Cap
The table below lists competitors of Ajanta Pharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jointown Pharmaceutical Group Co Ltd
SHG:600998
|
$3.81 Billion |
|
China Galaxy Securities Co Ltd
F:CGL
|
$3.82 Billion |
|
Grandblue Environment Co Ltd
SHG:600323
|
$3.82 Billion |
|
Carnival Corporation & plc
F:POH1
|
$3.82 Billion |
|
Peyto Exploration&Development Corp
TO:PEY
|
$3.81 Billion |
|
Kenon Holdings
TA:KEN
|
$3.81 Billion |
|
Amneal Pharmaceuticals, Inc. Class A Common Stock
NASDAQ:AMRX
|
$3.81 Billion |
|
KENON HLDGS LTD
F:76N
|
$3.81 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ajanta Pharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 35,673,600,000 to 37,902,900,000, a change of 2,229,300,000 (6.2%).
- Net income of 9,203,900,000 contributed positively to equity growth.
- Dividend payments of 3,493,700,000 reduced retained earnings.
- Share repurchases of 3,513,400,000 reduced equity.
- New share issuances of 100,000 increased equity.
- Other comprehensive income decreased equity by 1,378,900,000.
- Other factors increased equity by 1,411,300,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs9.20 Billion | +24.28% |
| Dividends Paid | Rs3.49 Billion | -9.22% |
| Share Repurchases | Rs3.51 Billion | -9.27% |
| Share Issuances | Rs100.00K | +0.0% |
| Other Comprehensive Income | Rs-1.38 Billion | -3.64% |
| Other Changes | Rs1.41 Billion | +3.72% |
| Total Change | Rs- | 6.25% |
Book Value vs Market Value Analysis
This analysis compares Ajanta Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.32x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 380.95x to 9.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | Rs7.41 | Rs2822.70 | x |
| 2006-03-31 | Rs8.22 | Rs2822.70 | x |
| 2007-03-31 | Rs8.76 | Rs2822.70 | x |
| 2008-03-31 | Rs10.24 | Rs2822.70 | x |
| 2009-03-31 | Rs11.93 | Rs2822.70 | x |
| 2010-03-31 | Rs14.04 | Rs2822.70 | x |
| 2011-03-31 | Rs17.37 | Rs2822.70 | x |
| 2012-03-31 | Rs22.57 | Rs2822.70 | x |
| 2013-03-31 | Rs29.77 | Rs2822.70 | x |
| 2014-03-31 | Rs44.93 | Rs2822.70 | x |
| 2015-03-31 | Rs63.70 | Rs2822.70 | x |
| 2016-03-31 | Rs88.79 | Rs2822.70 | x |
| 2017-03-31 | Rs118.73 | Rs2822.70 | x |
| 2018-03-31 | Rs154.61 | Rs2822.70 | x |
| 2019-03-31 | Rs170.06 | Rs2822.70 | x |
| 2020-03-31 | Rs198.54 | Rs2822.70 | x |
| 2021-03-31 | Rs229.33 | Rs2822.70 | x |
| 2022-03-31 | Rs251.76 | Rs2822.70 | x |
| 2023-03-31 | Rs264.43 | Rs2822.70 | x |
| 2024-03-31 | Rs283.11 | Rs2822.70 | x |
| 2025-03-31 | Rs302.81 | Rs2822.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ajanta Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 24.28%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.80%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 1.32x
- Recent ROE (24.28%) is above the historical average (22.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 10.09% | 4.96% | 0.92x | 2.22x | Rs893.00K |
| 2006 | 11.40% | 5.37% | 0.95x | 2.22x | Rs15.20 Million |
| 2007 | 12.71% | 5.68% | 0.96x | 2.33x | Rs31.23 Million |
| 2008 | 16.23% | 7.07% | 0.86x | 2.67x | Rs83.96 Million |
| 2009 | 16.19% | 7.28% | 0.75x | 2.95x | Rs97.21 Million |
| 2010 | 18.39% | 8.34% | 0.82x | 2.68x | Rs155.11 Million |
| 2011 | 22.16% | 10.04% | 0.97x | 2.28x | Rs278.30 Million |
| 2012 | 25.93% | 11.41% | 1.04x | 2.18x | Rs474.63 Million |
| 2013 | 28.52% | 12.16% | 1.28x | 1.83x | Rs727.99 Million |
| 2014 | 39.42% | 19.80% | 1.24x | 1.60x | Rs1.75 Billion |
| 2015 | 36.84% | 21.30% | 1.27x | 1.36x | Rs2.26 Billion |
| 2016 | 34.25% | 23.51% | 1.15x | 1.26x | Rs2.84 Billion |
| 2017 | 32.33% | 26.45% | 1.05x | 1.16x | Rs3.50 Billion |
| 2018 | 22.96% | 22.75% | 0.84x | 1.20x | Rs2.65 Billion |
| 2019 | 17.24% | 19.19% | 0.75x | 1.20x | Rs1.62 Billion |
| 2020 | 18.00% | 18.26% | 0.77x | 1.28x | Rs2.08 Billion |
| 2021 | 21.83% | 22.97% | 0.75x | 1.26x | Rs3.54 Billion |
| 2022 | 21.83% | 21.70% | 0.81x | 1.24x | Rs3.86 Billion |
| 2023 | 17.35% | 15.71% | 0.80x | 1.38x | Rs2.49 Billion |
| 2024 | 22.88% | 19.39% | 0.91x | 1.30x | Rs4.59 Billion |
| 2025 | 24.28% | 19.80% | 0.93x | 1.32x | Rs5.41 Billion |
Industry Comparison
This section compares Ajanta Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $45,564,604,304
- Average return on equity (ROE) among peers: 9.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ajanta Pharma Limited (AJANTPHARM) | Rs43.15 Billion | 10.09% | 0.31x | $3.81 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $83.97 Million | 10.78% | 0.83x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $13.69 Billion | 12.28% | 0.88x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $15.58 Billion | 12.42% | 0.44x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $5.44 Billion | 22.13% | 0.47x | $5.85 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $31.90 Billion | 25.98% | 0.88x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $245.74 Billion | 10.78% | 0.38x | $8.73 Billion |
About Ajanta Pharma Limited
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic a… Read more